中国自主研发的抗乳腺癌新药临床研究进展  

Progress of clinical research on new anti⁃breast cancer drugs independently developed in China

作　　者：张朦琦 徐兵河 ZHANG Mengqi;XU Binghe(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心(国家肿瘤临床医学研究中心,中国医学科学院肿瘤医院,北京协和医学院肿瘤医院,国家新药(抗肿瘤)临床研究中心),北京100021

出　　处：《中国肿瘤外科杂志》2024年第2期105-109,共5页Chinese Journal of Surgical Oncology

基　　金：中国医学科学院医学与健康科技创新工程项目(CIFMS)2021⁃I2M⁃1⁃014。

摘　　要：药物治疗是乳腺癌治疗的重要手段之一。近年来,中国乳腺癌的新药研发取得了长足进步,这些新药包括抗HER2药物、化疗药物、内分泌治疗药物和免疫治疗药物,涵盖了乳腺癌的各个分子亚型,其中许多临床研究改变了乳腺癌的临床实践。该文将对近年来中国自主研发的抗乳腺癌新药临床研究进行综述,以期为临床应用与后续研究提供参考。Systemic therapy is one of the important means for breast cancer treatment.In recent years,China has made great progress in the research and development on new anti-breast cancer drugs,which include anti-HER2 therapy,chemotherapy,endocrine therapy and immunotherapy drugs that covers various molecular subtypes of breast cancer,and many of these clinical studies have changed the clinical practice of breast cancer treatment.Therefore,this article summarizes the clinical researches on new anti-breast cancer drugs independently developed in China in recent years,aiming to provide insights for clinical application and future research.

关 键 词：乳腺肿瘤 中国研发药物 临床研究 靶向治疗 内分泌治疗 

分 类 号：R979.1[医药卫生—药品]